{"id":"alz-1101","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5961521","moleculeType":null,"molecularWeight":"501.59"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"While specific mechanistic details for ALZ-1101 are limited in public disclosures, Alleanza Pharmaceuticals' pipeline focuses on neurodegenerative diseases. The drug is in Phase 2 development, suggesting it has demonstrated preliminary efficacy and safety in early clinical trials for Alzheimer's disease or related cognitive decline.","oneSentence":"ALZ-1101 is an investigational therapeutic targeting Alzheimer's disease pathology, likely through modulation of amyloid or tau protein aggregation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:08:31.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease (Phase 2)"}]},"trialDetails":[{"nctId":"NCT01896180","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost","status":"COMPLETED","sponsor":"Alleanza Pharmaceuticals, Inc.","startDate":"2013-07","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ALZ-1101","genericName":"ALZ-1101","companyName":"Alleanza Pharmaceuticals, Inc.","companyId":"alleanza-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALZ-1101 is a medication being studied for the treatment of Primary Open Angle Glaucoma, Ocular Hypertension, and Elevated Intraocular Pressure. A clinical trial (NCT01896180) compared the safety and efficacy of ALZ-1101 to Latanoprost in patients with intraocular pressure inadequately controlled by Latanoprost.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}